Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 3, 2008, Pages 910-913

  Torlontano, Massimo ^a   Durante, Cosimo ^b   Torrente, Isabella ^a   Crocetti, Umberto ^a   Augello, Giovanni ^a   Ronga, Giuseppe ^b   Montesano, Teresa ^b   Travascio, Laura ^b   Verrienti, Antonella ^b   Bruno, Rocco ^c   Santini, Stefano ^a   D'Arcangelo, Palmina ^a   Dallapiccola, Bruno ^a,b   Filetti, Sebastiano ^b   Trischitta, Vincenzo ^a,b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Tinchi Pisticci Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; DEIODINASE 2; IODIDE PEROXIDASE; LEVOTHYROXINE SODIUM; RADIOACTIVE IODINE; THREONINE; THYROTROPIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THYROID CANCER; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL;

EID: 40849083521     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1067     Document Type: Article

References (15)

1. Bianco AC, Kim BW 2006 Deiodinases: implications of the local control of thyroid hormone action. J Clin Invest 116:2571-2579
2. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR 2002 Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 23:38-89
3. Celi FS, Canettieri G, Mentuccia D, Proietti-Pannunzi L, Fumarola A, Sibilla R, Predazzi V, Ferraro M, Andreoli M, Centanni M 2000 Structural organization and chromosomal localization of the human type II deiodinase gene. Eur J Endocrinol 143:267-271
4. Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR, Celi FS 2002 Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance. Evidence of interaction with the Trp64Arg variant of the b-3-adrenergic receptor. Diabetes 51:880-883
5. Peeters RP, van den Beld AW, Attalki H, van Toor H, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG, Visser TJ 2005 A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab 289:E75-E81
6. Silva JE, Larsen PR 1977 Pituitary nuclear 3,5,3′- triiodothyronine and thyrotropin secretion: an explanation for the effect of thyroxine. Science 198:617-620
7. Fliers E, Unmehopa UA, Alkemade A 2006 Functional neuroanatomy of thyroid hormone feedback in the human hypothalamus and pituitary gland. Mol Cell Endocrinol 251:1-8
8. Schneider MJ, Fiering SN, Pallud SE, Parlow AF, St Germain DL, Galton VA 2001 Targeted disruption of the type 2 selenodeiodinase gene (DIO2) results in a phenotype of pituitary resistance to T4. Mol Endocrinol 15:2137-2148
9. Canani LH, Capp C, Dora JM, Meyer EL, Wagner MS, Harney JW, Larsen PR, Gross JL, Bianco AC, Maia AL 2005 The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 90:3472-3478
10. Peeters RP, van Thoor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ 2003 Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 88:2880-2888
11. de Jong FJ, Peeters RP, den Heijer T, van der Deure WM, Hofman A, Uitterlinden AG, Visser TJ, Breteler MM 2007 The association of polymorphisms in the type 1 and 2 deiodinase genes with circulating thyroid hormone parameters and atrophy of the medial temporal lobe. J Clin Endocrinol Metab 92:636-640
12. Appelhof BC, Peeters RP, Wiersinga WM, Visser TJ, Wekking EM, Huyser J, Schene AH, Tijssen JG, Hoogendijk WJ, Fliers E 2005 Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. J Clin Endocrinol Metab 90:6296-6299
13. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, European Thyroid Cancer Taskforce 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol [Erratum (2006) 155:385] 154:787-803
14. Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA, Williams GH 2007 Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 49:461-466
15. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, Giannetti M, Taddei D, Centoni R, Scartabelli G, Rago T, Mammoli C, Elisei R, Vitti P 2005 Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 90:124-127